Skip to main content

Table 2 Patients’ characteristics and clinicopathological feature in subgroup analysis.

From: Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer

a) Metastatic de-novo versus metastatic recurrent

 

Metastatic recurrent (n = 26)

Metastatic de-novo (n = 10)

P value

Age median (range), (y.o.)

51 (33-74)

49 (35-64)

0.344

Subtype

  

0.079

 Luminal

19 (73.1%)

10 (100%)

 

 Triple negative

7 (26.9%)

0 (0%)

 

Number of previous chemotherapy regimens, (n)

  

0.515

 0

17 (65.4%)

5 (50.0%)

 

 1

6 (27.3%)

4 (40.0%)

 

 2

1 (3.8%)

1 (10.0%)

 

3

2 (7.7%)

0 (0%)

 

Previous endocrine therapy, (n)

16 (61.5%)

10 (100%)

0.021

Metastatic sites, (n)

  

0.473

 Visceral

16 (61.5%)

7 (70.0%)

 

 Non-visceral

10 (27.8%)

3 (30.0%)

 

b) No prior chemotherapy (CT) versus after chemotherapy.

 

No primary CT (n = 22)

After CT (n = 14)

P value

Age median (range), (y.o.)

51 (34-74)

47 (33-73)

0.243

Metastatic de-novo or recurrent, (n)

  

0.318

 Metastatic de-novo

5 (22.7%)

5 (35.7%)

 

 Metastatic recurrent

17 (77.3%)

9 (64.3%)

 

Subtype

  

0.433

 Luminal

17 (77.3%)

12 (85.7%)

 

 Triple negative

5 (22.7%)

2 (14.3%)

 

Previous endocrine therapy, (n)

16 (72.7%)

10 (71.4%)

0.611

Metastatic sites, (n)

  

0.374

 Visceral

15 (68.2%)

8 (57.1%)

 

 Non-visceral

7 (31.8%)

6 (42.9%)

 

c) Visceral metastasis versus non-visceral metastasis.

 

Visceral metastasis (n = 23)

Non-visceral metastasis (n = 13)

P value

Age median (range), (y.o.)

51.5 (33-73)

48 (34-74)

0.135

Metastatic de-novo or recurrent, (n)

  

0.473

 Metastatic de-novo

7 (30.4%)

3 (23.1%)

 

 Metastatic recurrent

16 (69.6%)

10 (76.9%)

 

Subtype

  

0.499

 Luminal

19 (82.6%)

10 (76.9%)

 

 Triple negative

4 (17.4%)

3 (23.1%)

 

Number of previous chemotherapy regimens, (n)

  

0.920

 0

14 (60.9%)

8 (61.5%)

 

 1

7 (30.4%)

3 (23.1%)

 

 2

1 (4.3%)

1 (7.7%)

 

3

1 (4.3%)

1 (7.7%)

 

Previous endocrine therapy, (n)

18 (78.3%)

8 (61.5%)

0.420

d) Luminal type versus triple negative breast cancer.

 

Luminal (n = 29)

TN (n = 7)

P value

Age median (range), (y.o.)

50 (33-74)

58 (36-73)

0.219

Metastatic de-novo or recurrent, (n)

  

0.079

 Metastatic de-novo

10 (22.7%)

0 (35.7%)

 

 Metastatic recurrent

19 (77.3%)

7 (64.3%)

 

Number of previous chemotherapy regimens, (n)

  

0.773

 0

17 (60.9%)

5 (61.5%)

 

 1

8 (30.4%)

2 (23.1%)

 

 2

2 (4.3%)

0 (7.7%)

 

3

2 (4.3%)

0 (7.7%)

 

Metastatic sites, (n)

  

0.499

 Visceral

19 (68.2%)

4 (57.1%)

 

 Non-visceral

10 (31.8%)

3 (42.9%)

 
 

Metastatic recurrent (n = 19)

Metastatic de-novo (n = 10)

P value

Age median (range), (y.o.)

50 (33-74)

49 (35-64)

0.618

Number of previous chemotherapy regimens, (n)

  

0.510

 0

12 (65.4%)

5 (50.0%)

 

 1

4 (27.3%)

4 (40.0%)

 

 2

1 (3.8%)

1 (10.0%)

 

3

2 (7.7%)

0 (0%)

 

Previous endocrine therapy, (n)

15 (61.5%)

10 (100%)

0.163

Metastatic sites, (n)

  

0.522

 Visceral

12 (61.5%)

7 (70.0%)

 

Non-visceral

7 (27.8%)

3 (30.0%)